The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study

This study of 86 patients with 12 months of follow-up was designed to determine whether topical corticosteroids or plasmin inhibitors have an effect on the outcome of photorefractive keratectomy. Patients were allocated randomly to either steroid (0.1% fluorometholone for 6 months), plasmin-inhibito...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 1994-09, Vol.101 (9), p.1565-1574
Hauptverfasser: O'BRART, D. P. S, LOHMANN, C. P, KLONOS, G, CORBETT, M. C, POLLOCK, W. S. T, KERR-MUIR, M. G, MARSHALL, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1574
container_issue 9
container_start_page 1565
container_title Ophthalmology (Rochester, Minn.)
container_volume 101
creator O'BRART, D. P. S
LOHMANN, C. P
KLONOS, G
CORBETT, M. C
POLLOCK, W. S. T
KERR-MUIR, M. G
MARSHALL, J
description This study of 86 patients with 12 months of follow-up was designed to determine whether topical corticosteroids or plasmin inhibitors have an effect on the outcome of photorefractive keratectomy. Patients were allocated randomly to either steroid (0.1% fluorometholone for 6 months), plasmin-inhibitor (aprotinin 40 IU/ml for 3 weeks), or control (no treatment) groups and underwent either -3.00- or -6.00-diopter (D) corrections. With -3.00-D corrections, the mean refractive change was significantly greater at 3 and 6 months (P < 0.05) in the steroid group compared with the control group. When steroids were discontinued, the difference became insignificant within 3 months. Similarly, with -6.00-D procedures the mean refractive change was greater at 6 weeks and 3 and 6 months (P < 0.01), but the refractive change again became insignificant 3 months after stopping steroid treatment. Four patients treated with steroids had a hyperopic shift greater than +2.00 D of that intended at 12 months. Similar overcorrections were not noted in the other treatment groups. There were no differences in refractive outcome between the aprotinin and control groups at any stage. With -6.00-D procedures, objective measurements of haze were significantly greater in the aprotinin group compared with the control group at 9 and 12 months (P < 0.05). With this exception, there were no differences in haze, forward or backward scatter of light, best-corrected visual acuity, or halo measurements between the groups. Corticosteroids can maintain a hyperopic shift during their administration, but this effect is reversed on cessation of treatment. Objective tests have shown that steroids have no effect on corneal haze or visual performance after PRK. There is no justification for routinely submitting all patients to long-term steroid regimens and their associated side effects. Treatment with aprotinin produced no beneficial effect on refractive outcome, and haze was greater in the -6.00-D procedures. The concept of modulating the plasminogen activator/plasmin system to regulate wound healing after PRK is discussed.
doi_str_mv 10.1016/S0161-6420(94)38032-8
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76717267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76717267</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-2a951fd27c740fe56c0822038e5cd2c005c01f7b624181516142c940a3e80b0e3</originalsourceid><addsrcrecordid>eNpFkM1u1DAUhS0EKtPCI1S6C4SoNAH_xkl3qOJPqsSCsh45zrXGNI6D7Yw0fUCeCwOjsjl3cc75dHUIuWT0LaOsffetCmtayembXl6JjgredE_IhinZN1Iz8ZRsHiPPyXnOPyilbSvkGTnTinPB1Ib8utsjoHNoS4booMTFWzOBjal4G3PBFP2YwcwjLJPJwc_g570ffImpNmZI6JKxxR8Q4lpsDLiFvXmo-qdz8HmtuAWTiymY2SIYV6Gw7GMl_O_eYzKlfhHDEa7BwJJiXvCvt4VUUTH4Bxy3EIeM6YCpCSbf4wi5rOPxBXnmzJTx5elekO8fP9zdfG5uv376cvP-tlm4UKXhplfMjVxbLalD1VracU5Fh8qO3FKqLGVODy2XrGOqrie57SU1Ajs6UBQX5PU_bn3v54q57ILPFqfJzBjXvNOtZpq3ugYvT8F1CDjuluSDScfdafjqvzr5Jte96wyz9fkxJrnSou_Ebwf9l50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76717267</pqid></control><display><type>article</type><title>The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>O'BRART, D. P. S ; LOHMANN, C. P ; KLONOS, G ; CORBETT, M. C ; POLLOCK, W. S. T ; KERR-MUIR, M. G ; MARSHALL, J</creator><creatorcontrib>O'BRART, D. P. S ; LOHMANN, C. P ; KLONOS, G ; CORBETT, M. C ; POLLOCK, W. S. T ; KERR-MUIR, M. G ; MARSHALL, J</creatorcontrib><description>This study of 86 patients with 12 months of follow-up was designed to determine whether topical corticosteroids or plasmin inhibitors have an effect on the outcome of photorefractive keratectomy. Patients were allocated randomly to either steroid (0.1% fluorometholone for 6 months), plasmin-inhibitor (aprotinin 40 IU/ml for 3 weeks), or control (no treatment) groups and underwent either -3.00- or -6.00-diopter (D) corrections. With -3.00-D corrections, the mean refractive change was significantly greater at 3 and 6 months (P &lt; 0.05) in the steroid group compared with the control group. When steroids were discontinued, the difference became insignificant within 3 months. Similarly, with -6.00-D procedures the mean refractive change was greater at 6 weeks and 3 and 6 months (P &lt; 0.01), but the refractive change again became insignificant 3 months after stopping steroid treatment. Four patients treated with steroids had a hyperopic shift greater than +2.00 D of that intended at 12 months. Similar overcorrections were not noted in the other treatment groups. There were no differences in refractive outcome between the aprotinin and control groups at any stage. With -6.00-D procedures, objective measurements of haze were significantly greater in the aprotinin group compared with the control group at 9 and 12 months (P &lt; 0.05). With this exception, there were no differences in haze, forward or backward scatter of light, best-corrected visual acuity, or halo measurements between the groups. Corticosteroids can maintain a hyperopic shift during their administration, but this effect is reversed on cessation of treatment. Objective tests have shown that steroids have no effect on corneal haze or visual performance after PRK. There is no justification for routinely submitting all patients to long-term steroid regimens and their associated side effects. Treatment with aprotinin produced no beneficial effect on refractive outcome, and haze was greater in the -6.00-D procedures. The concept of modulating the plasminogen activator/plasmin system to regulate wound healing after PRK is discussed.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/S0161-6420(94)38032-8</identifier><identifier>PMID: 7522315</identifier><identifier>CODEN: OPHTDG</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Adult ; Aged ; Aprotinin - administration &amp; dosage ; Aprotinin - pharmacology ; Biological and medical sciences ; Cornea - drug effects ; Cornea - physiology ; Cornea - surgery ; Double-Blind Method ; Eye ; Female ; Fluorometholone - administration &amp; dosage ; Fluorometholone - pharmacology ; Humans ; Laser Therapy ; Light ; Male ; Medical sciences ; Middle Aged ; Myopia - drug therapy ; Myopia - physiopathology ; Myopia - surgery ; Ophthalmic Solutions ; Pharmacology. Drug treatments ; Postoperative Care ; Prospective Studies ; Refraction, Ocular ; Scattering, Radiation ; Visual Acuity - drug effects</subject><ispartof>Ophthalmology (Rochester, Minn.), 1994-09, Vol.101 (9), p.1565-1574</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4257398$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7522315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'BRART, D. P. S</creatorcontrib><creatorcontrib>LOHMANN, C. P</creatorcontrib><creatorcontrib>KLONOS, G</creatorcontrib><creatorcontrib>CORBETT, M. C</creatorcontrib><creatorcontrib>POLLOCK, W. S. T</creatorcontrib><creatorcontrib>KERR-MUIR, M. G</creatorcontrib><creatorcontrib>MARSHALL, J</creatorcontrib><title>The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>This study of 86 patients with 12 months of follow-up was designed to determine whether topical corticosteroids or plasmin inhibitors have an effect on the outcome of photorefractive keratectomy. Patients were allocated randomly to either steroid (0.1% fluorometholone for 6 months), plasmin-inhibitor (aprotinin 40 IU/ml for 3 weeks), or control (no treatment) groups and underwent either -3.00- or -6.00-diopter (D) corrections. With -3.00-D corrections, the mean refractive change was significantly greater at 3 and 6 months (P &lt; 0.05) in the steroid group compared with the control group. When steroids were discontinued, the difference became insignificant within 3 months. Similarly, with -6.00-D procedures the mean refractive change was greater at 6 weeks and 3 and 6 months (P &lt; 0.01), but the refractive change again became insignificant 3 months after stopping steroid treatment. Four patients treated with steroids had a hyperopic shift greater than +2.00 D of that intended at 12 months. Similar overcorrections were not noted in the other treatment groups. There were no differences in refractive outcome between the aprotinin and control groups at any stage. With -6.00-D procedures, objective measurements of haze were significantly greater in the aprotinin group compared with the control group at 9 and 12 months (P &lt; 0.05). With this exception, there were no differences in haze, forward or backward scatter of light, best-corrected visual acuity, or halo measurements between the groups. Corticosteroids can maintain a hyperopic shift during their administration, but this effect is reversed on cessation of treatment. Objective tests have shown that steroids have no effect on corneal haze or visual performance after PRK. There is no justification for routinely submitting all patients to long-term steroid regimens and their associated side effects. Treatment with aprotinin produced no beneficial effect on refractive outcome, and haze was greater in the -6.00-D procedures. The concept of modulating the plasminogen activator/plasmin system to regulate wound healing after PRK is discussed.</description><subject>Adult</subject><subject>Aged</subject><subject>Aprotinin - administration &amp; dosage</subject><subject>Aprotinin - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cornea - drug effects</subject><subject>Cornea - physiology</subject><subject>Cornea - surgery</subject><subject>Double-Blind Method</subject><subject>Eye</subject><subject>Female</subject><subject>Fluorometholone - administration &amp; dosage</subject><subject>Fluorometholone - pharmacology</subject><subject>Humans</subject><subject>Laser Therapy</subject><subject>Light</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myopia - drug therapy</subject><subject>Myopia - physiopathology</subject><subject>Myopia - surgery</subject><subject>Ophthalmic Solutions</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Care</subject><subject>Prospective Studies</subject><subject>Refraction, Ocular</subject><subject>Scattering, Radiation</subject><subject>Visual Acuity - drug effects</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1u1DAUhS0EKtPCI1S6C4SoNAH_xkl3qOJPqsSCsh45zrXGNI6D7Yw0fUCeCwOjsjl3cc75dHUIuWT0LaOsffetCmtayembXl6JjgredE_IhinZN1Iz8ZRsHiPPyXnOPyilbSvkGTnTinPB1Ib8utsjoHNoS4booMTFWzOBjal4G3PBFP2YwcwjLJPJwc_g570ffImpNmZI6JKxxR8Q4lpsDLiFvXmo-qdz8HmtuAWTiymY2SIYV6Gw7GMl_O_eYzKlfhHDEa7BwJJiXvCvt4VUUTH4Bxy3EIeM6YCpCSbf4wi5rOPxBXnmzJTx5elekO8fP9zdfG5uv376cvP-tlm4UKXhplfMjVxbLalD1VracU5Fh8qO3FKqLGVODy2XrGOqrie57SU1Ajs6UBQX5PU_bn3v54q57ILPFqfJzBjXvNOtZpq3ugYvT8F1CDjuluSDScfdafjqvzr5Jte96wyz9fkxJrnSou_Ebwf9l50</recordid><startdate>19940901</startdate><enddate>19940901</enddate><creator>O'BRART, D. P. S</creator><creator>LOHMANN, C. P</creator><creator>KLONOS, G</creator><creator>CORBETT, M. C</creator><creator>POLLOCK, W. S. T</creator><creator>KERR-MUIR, M. G</creator><creator>MARSHALL, J</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19940901</creationdate><title>The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study</title><author>O'BRART, D. P. S ; LOHMANN, C. P ; KLONOS, G ; CORBETT, M. C ; POLLOCK, W. S. T ; KERR-MUIR, M. G ; MARSHALL, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-2a951fd27c740fe56c0822038e5cd2c005c01f7b624181516142c940a3e80b0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aprotinin - administration &amp; dosage</topic><topic>Aprotinin - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cornea - drug effects</topic><topic>Cornea - physiology</topic><topic>Cornea - surgery</topic><topic>Double-Blind Method</topic><topic>Eye</topic><topic>Female</topic><topic>Fluorometholone - administration &amp; dosage</topic><topic>Fluorometholone - pharmacology</topic><topic>Humans</topic><topic>Laser Therapy</topic><topic>Light</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myopia - drug therapy</topic><topic>Myopia - physiopathology</topic><topic>Myopia - surgery</topic><topic>Ophthalmic Solutions</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Care</topic><topic>Prospective Studies</topic><topic>Refraction, Ocular</topic><topic>Scattering, Radiation</topic><topic>Visual Acuity - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'BRART, D. P. S</creatorcontrib><creatorcontrib>LOHMANN, C. P</creatorcontrib><creatorcontrib>KLONOS, G</creatorcontrib><creatorcontrib>CORBETT, M. C</creatorcontrib><creatorcontrib>POLLOCK, W. S. T</creatorcontrib><creatorcontrib>KERR-MUIR, M. G</creatorcontrib><creatorcontrib>MARSHALL, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'BRART, D. P. S</au><au>LOHMANN, C. P</au><au>KLONOS, G</au><au>CORBETT, M. C</au><au>POLLOCK, W. S. T</au><au>KERR-MUIR, M. G</au><au>MARSHALL, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>1994-09-01</date><risdate>1994</risdate><volume>101</volume><issue>9</issue><spage>1565</spage><epage>1574</epage><pages>1565-1574</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><coden>OPHTDG</coden><abstract>This study of 86 patients with 12 months of follow-up was designed to determine whether topical corticosteroids or plasmin inhibitors have an effect on the outcome of photorefractive keratectomy. Patients were allocated randomly to either steroid (0.1% fluorometholone for 6 months), plasmin-inhibitor (aprotinin 40 IU/ml for 3 weeks), or control (no treatment) groups and underwent either -3.00- or -6.00-diopter (D) corrections. With -3.00-D corrections, the mean refractive change was significantly greater at 3 and 6 months (P &lt; 0.05) in the steroid group compared with the control group. When steroids were discontinued, the difference became insignificant within 3 months. Similarly, with -6.00-D procedures the mean refractive change was greater at 6 weeks and 3 and 6 months (P &lt; 0.01), but the refractive change again became insignificant 3 months after stopping steroid treatment. Four patients treated with steroids had a hyperopic shift greater than +2.00 D of that intended at 12 months. Similar overcorrections were not noted in the other treatment groups. There were no differences in refractive outcome between the aprotinin and control groups at any stage. With -6.00-D procedures, objective measurements of haze were significantly greater in the aprotinin group compared with the control group at 9 and 12 months (P &lt; 0.05). With this exception, there were no differences in haze, forward or backward scatter of light, best-corrected visual acuity, or halo measurements between the groups. Corticosteroids can maintain a hyperopic shift during their administration, but this effect is reversed on cessation of treatment. Objective tests have shown that steroids have no effect on corneal haze or visual performance after PRK. There is no justification for routinely submitting all patients to long-term steroid regimens and their associated side effects. Treatment with aprotinin produced no beneficial effect on refractive outcome, and haze was greater in the -6.00-D procedures. The concept of modulating the plasminogen activator/plasmin system to regulate wound healing after PRK is discussed.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>7522315</pmid><doi>10.1016/S0161-6420(94)38032-8</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0161-6420
ispartof Ophthalmology (Rochester, Minn.), 1994-09, Vol.101 (9), p.1565-1574
issn 0161-6420
1549-4713
language eng
recordid cdi_proquest_miscellaneous_76717267
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aprotinin - administration & dosage
Aprotinin - pharmacology
Biological and medical sciences
Cornea - drug effects
Cornea - physiology
Cornea - surgery
Double-Blind Method
Eye
Female
Fluorometholone - administration & dosage
Fluorometholone - pharmacology
Humans
Laser Therapy
Light
Male
Medical sciences
Middle Aged
Myopia - drug therapy
Myopia - physiopathology
Myopia - surgery
Ophthalmic Solutions
Pharmacology. Drug treatments
Postoperative Care
Prospective Studies
Refraction, Ocular
Scattering, Radiation
Visual Acuity - drug effects
title The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy : a prospective, randomized, observer-masked study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A27%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20topical%20corticosteroids%20and%20plasmin%20inhibitors%20on%20refractive%20outcome,%20haze,%20and%20visual%20performance%20after%20photorefractive%20keratectomy%20:%20a%20prospective,%20randomized,%20observer-masked%20study&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=O'BRART,%20D.%20P.%20S&rft.date=1994-09-01&rft.volume=101&rft.issue=9&rft.spage=1565&rft.epage=1574&rft.pages=1565-1574&rft.issn=0161-6420&rft.eissn=1549-4713&rft.coden=OPHTDG&rft_id=info:doi/10.1016/S0161-6420(94)38032-8&rft_dat=%3Cproquest_pubme%3E76717267%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76717267&rft_id=info:pmid/7522315&rfr_iscdi=true